News

NexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidation

  • Shares of NexImmune (NASDAQ: NEXI ) stock are skyrocketing higher ahead of the company's special meeting of stockholders. The meeting was initially set for Dec. 21 with a record date of Nov. 6.
    01/09/2024

Dear NEXI Stock Fans, Mark Your Calendars for Jan. 18

  • Inexplicably, shares of embattled immunotherapy specialist NexImmune (NASDAQ: NEXI ) are skyrocketing more than 190% despite efforts to dissolve the business. An earlier attempt to vote on the liquidation and dissolution of the biotechnology enterprise failed due to a lack of quorum.
    01/03/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

NexImmune, Inc. (NEXI) can hold. Click on Rating Page for detail.

The price of NexImmune, Inc. (NEXI) is 7.14 and it was updated on 2024-02-22 13:00:48.

Currently NexImmune, Inc. (NEXI) is in undervalued.

News
    
News

NEXI Stock Halted: What's Going on With NexImmune Shares Today?

  • Following a dramatic spike in shares yesterday, exchange operators at Nasdaq pulled the circuit breaker on NexImmune (NASDAQ: NEXI ). Though seemingly offering innovative solutions to disease treatment, the biotechnology firm has lost almost all its value since its initial public offering in 2021.
    Fri, Dec. 01, 2023

Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping

  • Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by more than 40% even as the Nasdaq 100 and S&P 500 indices pulled back.
    Fri, Dec. 01, 2023

Why Is NexImmune (NEXI) Stock Up 353% Today?

  • NexImmune (NASDAQ: NEXI ) stock is heading higher on Friday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases for filings with the Securities and Exchange Commission (SEC) that help explain why NEXI stock is up today.
    Fri, Dec. 01, 2023

How to Identify Trends With Penny Stocks in 2023

  • Use these tips for identifying penny stocks trends in 2023 The post How to Identify Trends With Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
    Fri, Feb. 17, 2023

Why Is NexImmune (NEXI) Stock Up 65% Today?

  • NexImmune (NASDAQ: NEXI ) stock is rocketing higher on Thursday following the release of positive preclinical trial data. According to a press release from the company, preclinical data shows AIM ACT T cells are effective in aiding BiTE therapy.
    Thu, Feb. 16, 2023
SEC Filings
SEC Filings

NexImmune, Inc. (NEXI) - DEFA14A

  • SEC Filings
  • 02/06/2024

NexImmune, Inc. (NEXI) - 424B5

  • SEC Filings
  • 02/05/2024

NexImmune, Inc. (NEXI) - DEFA14A

  • SEC Filings
  • 01/18/2024

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 11/22/2023

NexImmune, Inc. (NEXI) - DEF 14A

  • SEC Filings
  • 11/20/2023

NexImmune, Inc. (NEXI) - PRE 14A

  • SEC Filings
  • 11/09/2023

NexImmune, Inc. (NEXI) - DEF 14A

  • SEC Filings
  • 09/25/2023

NexImmune, Inc. (NEXI) - PRE 14A

  • SEC Filings
  • 09/13/2023

NexImmune, Inc. (NEXI) - 3

  • SEC Filings
  • 09/08/2023

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 07/07/2023

NexImmune, Inc. (NEXI) - SC 13D

  • SEC Filings
  • 04/07/2023

NexImmune, Inc. (NEXI) - 424B5

  • SEC Filings
  • 04/07/2023

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 04/06/2023

NexImmune, Inc. (NEXI) - DEFA14A

  • SEC Filings
  • 04/04/2023

NexImmune, Inc. (NEXI) - DEF 14A

  • SEC Filings
  • 04/04/2023

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 03/31/2023

NexImmune, Inc. (NEXI) - S-8

  • SEC Filings
  • 03/28/2023

NexImmune, Inc. (NEXI) - SC 13G/A

  • SEC Filings
  • 02/15/2023

NexImmune, Inc. (NEXI) - SC 13G/A

  • SEC Filings
  • 02/13/2023

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 11/29/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 11/25/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 11/17/2022

NexImmune, Inc. (NEXI) - 424B5

  • SEC Filings
  • 06/17/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 06/15/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 06/07/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 06/02/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 05/09/2022

NexImmune, Inc. (NEXI) - 3

  • SEC Filings
  • 05/09/2022

NexImmune, Inc. (NEXI) - DEFA14A

  • SEC Filings
  • 05/03/2022

NexImmune, Inc. (NEXI) - DEF 14A

  • SEC Filings
  • 05/03/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 04/07/2022

NexImmune, Inc. (NEXI) - 3

  • SEC Filings
  • 04/07/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 03/30/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 03/28/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 03/24/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 03/23/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 03/22/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 03/21/2022

NexImmune, Inc. (NEXI) - EFFECT

  • SEC Filings
  • 03/17/2022

NexImmune, Inc. (NEXI) - EFFECT

  • SEC Filings
  • 03/17/2022

NexImmune, Inc. (NEXI) - CORRESP

  • SEC Filings
  • 03/14/2022

NexImmune, Inc. (NEXI) - UPLOAD

  • SEC Filings
  • 03/11/2022

NexImmune, Inc. (NEXI) - S-8

  • SEC Filings
  • 03/09/2022

NexImmune, Inc. (NEXI) - S-3

  • SEC Filings
  • 03/09/2022

NexImmune, Inc. (NEXI) - SC 13G

  • SEC Filings
  • 02/22/2022

NexImmune, Inc. (NEXI) - SC 13G

  • SEC Filings
  • 02/18/2022

NexImmune, Inc. (NEXI) - SC 13G/A

  • SEC Filings
  • 02/14/2022

NexImmune, Inc. (NEXI) - SC 13G

  • SEC Filings
  • 02/14/2022

NexImmune, Inc. (NEXI) - SC 13G

  • SEC Filings
  • 02/11/2022

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 12/22/2021

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 07/09/2021

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 06/09/2021

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 05/19/2021

NexImmune, Inc. (NEXI) - SC 13G

  • SEC Filings
  • 04/12/2021

NexImmune, Inc. (NEXI) - SC 13G

  • SEC Filings
  • 03/31/2021

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 03/12/2021

NexImmune, Inc. (NEXI) - S-8

  • SEC Filings
  • 02/25/2021

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 02/19/2021

NexImmune, Inc. (NEXI) - 424B4

  • SEC Filings
  • 02/16/2021

NexImmune, Inc. (NEXI) - 4

  • SEC Filings
  • 02/16/2021

NexImmune, Inc. (NEXI) - EFFECT

  • SEC Filings
  • 02/12/2021

NexImmune, Inc. (NEXI) - EFFECT

  • SEC Filings
  • 02/11/2021

NexImmune, Inc. (NEXI) - S-1MEF

  • SEC Filings
  • 02/11/2021

NexImmune, Inc. (NEXI) - S-1/A

  • SEC Filings
  • 02/11/2021

NexImmune, Inc. (NEXI) - 3

  • SEC Filings
  • 02/11/2021

NexImmune, Inc. (NEXI) - CERT

  • SEC Filings
  • 02/10/2021

NexImmune, Inc. (NEXI) - CORRESP

  • SEC Filings
  • 02/09/2021

NexImmune, Inc. (NEXI) - 8-A12B

  • SEC Filings
  • 02/09/2021

NexImmune, Inc. (NEXI) - S-1/A

  • SEC Filings
  • 02/08/2021

NexImmune, Inc. (NEXI) - S-1

  • SEC Filings
  • 01/19/2021

NexImmune, Inc. (NEXI) - DRSLTR

  • SEC Filings
  • 01/15/2021

NexImmune, Inc. (NEXI) - DRS/A

  • SEC Filings
  • 01/15/2021

NexImmune, Inc. (NEXI) - UPLOAD

  • SEC Filings
  • 01/11/2021

NexImmune, Inc. (NEXI) - DRS

  • SEC Filings
  • 12/14/2020

NexImmune, Inc. (NEXI) - D

  • SEC Filings
  • 02/22/2019

NexImmune, Inc. (NEXI) - D

  • SEC Filings
  • 02/01/2018

NexImmune, Inc. (NEXI) - D

  • SEC Filings
  • 02/13/2015

NexImmune, Inc. (NEXI) - D

  • SEC Filings
  • 07/25/2014

NexImmune, Inc. (NEXI) - D

  • SEC Filings
  • 12/27/2013

NexImmune, Inc. (NEXI) - D

  • SEC Filings
  • 02/03/2012
Press Releases
StockPrice Release
More Headlines
News

Why Is NexImmune (NEXI) Stock Down 4% Today?

  • NexImmune (NASDAQ: NEXI ) stock is falling on Friday as the immunotherapies company's shares come off of a recent high earlier this week. The NEXI stock rally started earlier this week and has seen the company's shares go through several rises and falls.
  • 01/20/2023

NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  • GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET.
  • 09/09/2022

NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug

  • NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
  • 07/15/2022

Why Is NexImmune (NEXI) Stock Up 30% Today?

  • NexImmune appears to be making headway in the company's ongoing battle against HPV-related cancers -- and NEXI stock is heading higher today. The post Why Is NexImmune (NEXI) Stock Up 30% Today?
  • 07/15/2022

What Makes NexImmune, Inc. (NEXI) a New Buy Stock

  • NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  • 06/10/2022

Executives Buy More Than $1M Of 5 Penny Stocks

  • The Dow Jones jumped around 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.
  • 03/29/2022

NexImmune, Zephyr Join Forces For Oncology Target Discovery, Validation

  • NexImmune Inc (NASDAQ: NEXI) and Zephyr AI have announced a strategic partnership focusing on discovering and validating novel targets for new T-cell-mediated therapies in oncology.  The collaboration will combine Zephyr's artificial intelligence and algorithmic.
  • 03/17/2022

NexImmune to Present at the Barclays 2022 Global Healthcare Conference

  • GAITHERSBURG, Md., March 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the Barclays 2022 Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. Eastern Time.
  • 03/10/2022

NexImmune to Announce Third Quarter 2021 Financial Results and Provide Corporate Update on November 12, 2021

  • GAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report third quarter financial results and provide a corporate update on Friday, November 12, 2021, via press release, prior to the market open.
  • 11/08/2021

NexImmune to Present at The Society for Immunotherapy of Cancer 36th Anniversary Annual Meeting

  • GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that two abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington, D.C., being held November 10-14, 2021.
  • 11/03/2021

NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference

  • GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present at the 2021 Cantor Virtual Global Healthcare Conference Wednesday, September 29, 2021 at 2:00 PM Eastern time.
  • 09/27/2021

NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

  • GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference today, September 10, 2021 at 1:15p.m. Eastern time.
  • 09/10/2021

NexImmune Strengthens Management Team with Key Appointments

  • GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Jack A. Ragheb, MD, PhD, has been appointed to the newly created position of Senior Vice President, Translational Science, bringing more than 30 years of experience in translational and clinical research in the fields of cell therapy, gene therapy, immunology and virology. In addition, Matt Schiller has been appointed to Head of Business Development, bringing more than 20 years of business development experience across developmental stage life science companies and large pharma.
  • 07/14/2021

NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference

  • GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 at 9:20 a.m. Eastern time.
  • 06/16/2021

NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting

  • GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually from June 4 – June 8, 2021.
  • 05/19/2021

NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs

  • GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.
  • 04/21/2021

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

  • Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.
  • 02/20/2021

NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

  • GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response, today announced the closing of its previously announced upsized initial public offering of 7,441,650 shares of its common stock at a price to the public of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase 970,650 additional shares. Including the option exercise, the gross proceeds to NexImmune from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $126.5 million.
  • 02/17/2021

U.S. IPO Weekly Recap: IPO Frenzy Brings The Year's Largest Deal And Biggest Pop In A 17 IPO Week

  • The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble, which completed the year's largest deal so far, and Chinese cloud services provider Cloopen Group, which bagged the biggest pop of 2021 to date.
  • 02/14/2021
Unlock
NEXI Ratings Summary
NEXI Quant Ranking